跳转至内容
Merck
CN

C7869

Sigma-Aldrich

CEP-701 hydrate

≥98% (HPLC)

别名:

KT-5555 hydrate, Lestaurtinib hydrate

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C26H21N3O4 · xH2O
分子量:
439.46 (anhydrous basis)
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

质量水平

方案

≥98% (HPLC)

表单

powder

颜色

white

溶解性

DMSO: >10 mg/mL

储存温度

−20°C

SMILES字符串

O.C[C@]12O[C@H](C[C@]1(O)CO)n3c4ccccc4c5c6C(=O)NCc6c7c8ccccc8n2c7c35

InChI

1S/C26H21N3O4.H2O/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28;/h2-9,18,30,32H,10-12H2,1H3,(H,27,31);1H2/t18-,25+,26+;/m1./s1

InChI key

LPOQWFBZBJTLEO-GMEYHWBASA-N

应用

CEP-701 hydrate has been used as a tyrosine kinase inhibitor:
  • to study its effects on early growth response protein (EGR) genes and nerve growth factor (NGF) stimulation in human epithelial cells
  • as a supplement in reservoir solution for co-crystallization studies with human receptor-interacting protein kinase 4 (RIPK4)
  • as an FMS-like tyrosine kinase 3 (FLT3) inhibitor-gold nanoparticle conjugate to study its effects on acute myeloid leukemia

生化/生理作用

CEP-701 hydrate, also known as Lestaurtinib, can repress Janus kinase 2/signal transducer and activator of transcription 5 (JAK2/STAT5) signaling by the specific inhibition of JAK2.
CEP-701 is a Flt-3 receptor tyrosine kinase inhibitor.

特点和优势

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Bobe Petrushev et al.
International journal of nanomedicine, 11, 641-660 (2016-03-02)
Every year, in Europe, acute myeloid leukemia (AML) is diagnosed in thousands of adults. For most subtypes of AML, the backbone of treatment was introduced nearly 40 years ago as a combination of cytosine arabinoside with an anthracycline. This therapy
Tania Diaz et al.
PloS one, 6(4), e18856-e18856 (2011-05-03)
Standard cytotoxic chemotherapy for Hodgkin Lymphoma (HL) has changed little in 30 years; the treatment for patients with relapsed or refractory disease remains challenging and novel agents are under development. JAK/STAT constitutive activation plays an important role in the pathogenesis
Christine S Huang et al.
Structure (London, England : 1993), 26(5), 767-777 (2018-05-01)
Receptor-interacting protein kinase 4 (RIPK4) is a highly conserved regulator of epidermal differentiation. Members of the RIPK family possess a common kinase domain as well as unique accessory domains that likely dictate subcellular localization and substrate preferences. Mutations in human
Timea Simon et al.
Nanoscale research letters, 10(1), 466-466 (2015-12-03)
Releasing drug molecules at the targeted location could increase the clinical outcome of a large number of anti-tumor treatments which require low systemic damage and low side effects. Nano-carriers of drugs show great potential for such task due to their
M Rochman et al.
Mucosal immunology, 8(4), 785-798 (2014-11-13)
Although interleukin (IL)-13 and neurotrophins are functionally important for the pathogenesis of immune responses, the interaction of these pathways has not been explored. Herein, by interrogating IL-13-induced responses in human epithelial cells we show that neurotrophic tyrosine kinase receptor, type

商品

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门